Join to view full profile
2004 Hayes StSte 350Nashville, TN 37203
Phone+1 615-312-3333
Fax+1 615-320-7091
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 1 invite waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Nancy Peacock, MD is an oncologist in Nashville, Tennessee. She is currently licensed to practice medicine in Tennessee and Texas. She is an Assistant Professor at University of Tennessee Health.
Education & Training
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 1991 - 1993- University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineResidency, Internal Medicine, 1988 - 1991
University of Missouri-Columbia School of MedicineClass of 1988
Certifications & Licensure
TN State Medical License 1995 - 2028
TX State Medical License 1989 - 1996
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2013-2017
- CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2013-2017
Publications & Presentations
PubMed
- 8 citationsA Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC).Denise A. Yardley, Robyn R. Young, Kerin B. Adelson, Andrea Silber, Jose E. Najera
Clinical Breast Cancer. 2021-10-28 - 5 citationsPhase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapyDenise A. Yardley, N. W. Peacock, Brooke R. Daniel, Betrand Anz, David C. Molthrop
Breast Cancer Research and Treatment. 2020-02-14 - 15 citationsA Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine CancersJohanna C. Bendell, Ahmed Zakari, Evan Z. Lang, David M. Waterhouse, Douglas Flora
Cancer Investigation. 2016-04-29
